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ABSTRACT
Prostate cancer (PCa) is one of the most incident cancers worldwide but clinical 
and pathological parameters have limited ability to discriminate between clinically 
significant and indolent PCa. Altered expression of histone methyltransferases and 
histone methylation patterns are involved in prostate carcinogenesis. SMYD3 transcript 
levels have prognostic value and discriminate among PCa with different clinical 
aggressiveness, so we decided to investigate its putative oncogenic role on PCa.
We silenced SMYD3 and assess its impact through in vitro (cell viability, cell cycle, 
apoptosis, migration, invasion assays) and in vivo (tumor formation, angiogenesis). 
We evaluated SET domain’s impact in PCa cells’ phenotype. Histone marks deposition 
on SMYD3 putative target genes was assessed by ChIP analysis.
Knockdown of SMYD3 attenuated malignant phenotype of LNCaP and PC3 cell 
lines. Deletions affecting the SET domain showed phenotypic impact similar to 
SMYD3 silencing, suggesting that tumorigenic effect is mediated through its histone 
methyltransferase activity. Moreover, CCND2 was identified as a putative target gene 
for SMYD3 transcriptional regulation, through trimethylation of H4K20.
Our results support a proto-oncogenic role for SMYD3 in prostate carcinogenesis, 
mainly due to its methyltransferase enzymatic activity. Thus, SMYD3 overexpression 
is a potential biomarker for clinically aggressive disease and an attractive therapeutic 
target in PCa.
BACKGROUND
Genetic alterations have been historically consider­
ed the main driving force of cancer initiation and 
progression, although more recently a prominent role 
for epigenetic modifications has been acknowledged 
[1]. In addition to aberrant gene promoter methylation, 
alterations in chromatin modification patterns due to post-
translational modifications (PTMs) of histones have been 
demonstrated in cancer and emerged as potential key 
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players in neoplastic transformation. Specifically, diverse 
PTMs might occur in amino tail domains, including 
lysine acetylation, lysine and arginine methylation, 
serine and threonine phosphorylation, ADPribosylation, 
ubiquitination, and sumoylation [2]. Histone methylation 
is carried out by histone methyltransferases (HMTs) 
whereas histone demethylases (HDMs) antagonize 
their action [3, 4]. Depending on the target residue and 
the state of methylation (i.e., whether it is mono-, di- 
or trimethylated), PTMs may positively or negatively 
regulate gene transcription. In cancer cells, deregulation 
of HMTs or HDMs has been associated with altered post-
translational control of cellular proteins affecting key 
signaling networks [5, 6].
Among HMTs, SET and MYND domain-containing 
protein 3 (SMYD3) belongs to a subfamily of SET 
domain-containing proteins with an important role in 
transcriptional regulation [7]. Its methyltransferase 
activity is highly dependent on two amino acid sequences, 
NHSC and EEL, located within the SET domain [7]. 
SMYD3 was firstly described as having dimethyl- and 
trimethyltransferase activity at lysine 4 of histone H3 
(H3K4), but recently it has been reported that SMYD3 
also methylates H4K5 and H4K20, as well as other non-
histonic proteins, such as vascular endothelial growth 
factor receptor 1 (VEGFR1) [8–10]. An oncogenic role 
of SMYD3 has been suggested in several cancer models, 
including colorectal, hepatocellular, cervical and breast 
carcinomas [7, 11–14]. Indeed, SMYD3 was shown to 
induce transcriptional activation of several downstream 
genes, including Nkx2.8, WNT10B, RIZ1, c-Met, 15-
LOX-1, MMP9 and AR [7, 11, 12, 15–18]. Interestingly, 
since SMYD3 is able to promote either the active 
H3K4me3 or the repressive H4K20me3 marks, it has 
been suggested that it might act either by repressing tumor 
suppressor genes or inducing oncogenes’ expression [8].
Prostate cancer (PCa), one of the most incident 
cancers worldwide, remains a significant clinical challenge 
as PSA screening led to substantial over diagnosis and 
overtreatment of patients [19]. Thus, additional efforts 
are needed to better identify and characterize aggressive 
tumors, allowing for more appropriate therapeutic 
strategies that will avoid unnecessary and potentially 
harmful interventions [20]. We have previously reported 
that PCa tissues displayed higher SMYD3 levels 
compared to normal prostate, especially at advanced 
disease stages. Moreover, we demonstrated that SMYD3 
transcript levels convey prognostically important 
information and might discriminate among PCa with 
different clinical aggressiveness [21]. Nevertheless, how 
SMYD3 deregulated expression and respective histone 
marks impact on PCa development and progression is 
still largely unknown. Herein, we sought to ascertain the 
impact of SMYD3 methyltransferase activity on PCa cells 
phenotype. Knockdown of SMYD3 in LNCaP and PC3 
cells attenuated the malignant phenotype, both in vitro 
and in vivo. This effect was mostly mediated through 
SMYD3 histone methyltransferase activity. Moreover, 
cell cycle regulation surfaced as the main cellular pathway 
influenced by SMYD3 methyltransferase activity, and 
CCND2 was identified as a putative target gene for 
SMYD3 transcriptional regulation through trimethylation 
of H4K20. Thus, a proto-oncogenic role for SMYD3 in 
prostate carcinogenesis is suggested, mainly due to its 
methyl transferase enzymatic activity.
RESULTS
Impact of SMYD3 silencing on the malignant 
phenotype of PCa Cells
To select the most suitable in vitro model, SMYD3 
expression levels were assessed in PCa cell lines LNCaP, 
VCaP, DU145 and PC3. All cell lines expressed SMYD3, 
although at variable levels (Figure 1A). The cell lines 
displaying the highest expression levels among the 
androgen-sensitive and the androgen-refractory were 
then selected for further analysis (LNCaP and PC3, 
respectively). Lentiviral particles efficiently silenced 
SMYD3 in those two cell lines, at transcript and protein 
level (Figure 1B).
The MTT assay showed a 35% decrease in viability 
of PC3 cells, although the opposite was apparent in 
LNCaP cells, at 72 h (Figure 2A). Interestingly, SMYD3-
depleted PC3 cells displayed a statistically significant 
cell cycle arrest at S phase, whereas in LNCaP cells a 
reduction was depicted at G2/M transition. No significant 
differences in Sub-G1 population were observed for any 
cell line (Figure 2B). Similarly, a significant increase 
in BrdU uptake was observed in PC3 SMYD3-depleted 
cells (p = 0.029). Moreover, knockdown of SMYD3 
induced a significant increase in apoptosis in both cell 
lines (Figure 2C).
A significant decrease in migration rate as well 
as in invasiveness capacity was also demonstrated in 
SMYD3-depleted PC3 cells (Figure 2E and 2F), whereas 
for LNCaP a statistically significant reduction was only 
observed in cell migration (Figure 2D).
Effects of SMYD3 knockdown on tumor 
formation and vessel density in vivo
The CAM assay was performed to evaluate the 
effect of SMYD3 on tumor growth and angiogenesis 
in vivo (Figure 3A–3C). The areas occupied by formed 
tumors were smaller in sh-SMYD3 LNCaP and PC3 
compared to controls, but this difference was only 
statistically significant for PC3 (p = 0.023, Figure 3A). No 
statistically significant difference was apparent in linear 
vessel density counted ex ovo between sh-scramble and 
sh-SMYD3 cells, for both cell lines.
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SMYD3 putative oncogenic function is associated 
with the histone methyltransferase activity
The impact of SMYD3 knockdown on mono-, di- and 
trimethylation levels of H3K4, as well as on trimethylation 
of H3K27 and H4K20 was assessed using Western-blot 
(Figure 4). Both LNCaP and PC3 cells showed a paradoxical 
increment in H3K4me2 and H3K4me3 as well as a decrease 
in H3K4me1, but these differences did not reach statistical 
significance. Interestingly, SMYD3-silenced LNCaP and 
PC3 cells displayed an increase (although not significant) 
in global levels of the repressive mark H3K27me3. 
Concerning the repressive mark, H4K20me3, decreased 
expression was displayed by both cell lines, although in PC3 
the effect was more pronounced.
To assess whether the previously documented 
phenotypic effects were due to SMYD3 
methyltransferase activity, sh-SMYD3 PCa cells 
were transfected with mutant SMYD3 deleted for 
main components of SMYD3 SET domain, the EEL 
and NHSC amino acid sequences and compared with 
forced SMYD3 expression in sh-SMYD3 PC3 cells 
(Figure 5A). In the absence of one of those sequences, 
cell viability and invasion capacity were reduced and 
apoptosis was increased (Figure 5B, 5C and 5D). These 
effects were more pronounced when the SMYD3-EEL 
domain was deleted. Concerning invasion capability, 
only SMYD3-∆EEL-PC3 cells disclosed a statistically 
significant reduction when compared to the control cells 
(Figure 5D).
SMYD3 knockdown leads to CCND2 restored 
expression through downregulation of 
H4K20me3 mark
To identify putative target genes of SMYD3 histone 
methyltransferase activity, expression profile of selected 
genes involved in cell cycle, apoptosis, DNA repair, 
mTOR and MAPK/ERK pathways was evaluated after 
SMYD3 knockdown (Figure 6A). From the six genes 
that met the selection criteria, three were found to be 
overexpressed in SMYD3-silenced PC3 cells, and two 
in LNCaP. The only downregulated gene was observed 
in SMYD3-silenced PC3 cell line (Supplementary Table 
S1). Remarkably, Cyclin D2 (CCND2) was overexpressed 
both in expression array, qRT-PCR assay and western blot 
analysis for the two cell lines when SMYD3 expression 
was knockdown (Figure 6B).
Interestingly, in primary tumors, a large proportion 
of PCa cases displayed SMYD3 overexpression 
(immunoscore 3+), whereas cases with Cyclin D2 
underexpression predominated (Figure 7). Although 
a trend for an inverse correlation between SMYD3 
and Cyclin D2 expression is graphically suggested, no 
statistically significance was attained. Remarkably, when 
the patient cohort was stratified according to tumor grade, 
increased SMYD3 immunoexpression was associated with 
higher Gleason score (p = 0.002), 
Moreover, ChIP analysis of CCND2 promoter region 
(Figure 6C) showed a decrease in the H4K20me3 mark, 
concomitantly with the silencing of SMYD3, although no 
Figure 1: SMYD3 expression levels in PCa cell lines. A. Expression levels of SMYD3 in VCaP, LNCaP, DU145 and PC3 cell lines. 
B. The efficiency of SMYD3 knockdown was confirmed in LNCaP and PC3 cells. mRNA levels were assessed using real-time RT-PCR 
(upper) and protein levels using Western-blot (lower). **p < 0.01 (Mann-Whitney U-test).
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Figure 2: Impact of SMYD3 silencing in the malignant phenotype of PCa cells. A. Cell viability in LNCaP and PC3: 
quantification of cell viability by MTT assay in sh-scramble and sh-SMYD3 at 0 h, 24 h, 48 h and 72 h in culture. B. Cell cycle distribution 
of cell lines by flow cytometry. C. Quantification of apoptosis by APOPercentage kit of sh-Scramble, sh-SMYD3 LNCaP and sh-SMYD3 
PC3 cells at 72 h. Wound-healing scratch assay in sh-scramble and sh-SMYD3 LNCaP D. and PC3 E. cells: the left panels show the 
migration rate at 48 h and 72 h or 16 h and 24 h, in LNCaP and PC3, respectively, and the right panels display the illustrative images at the 
beginning and end point of the assay. F. Invasive ability was assessed by a Matrigel Invasion assay in sh-scramble and sh-SMYD3 LNCaP 
and PC3, cells at 48 h and 24 h, respectively. Results were normalized to the data obtained with sh-scramble cells. *p < 0.05, **p < 0.01, 
***p < 0.001 (Mann-Whitney U-test).
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significant differences in H3K4me3 or H3K27me3 levels 
were apparent in none of the three regions tested (Figure 6D).
Methylation evaluation was also performed to 
ascertain whether SMYD3 depletion in PC-3 and LNCaP 
cells led to alteration of methylation patterns at CCND2 
promoter. After SMYD3 silencing, there was no statistical 
difference in CCND2 promoter methylation levels in both 
cell lines (Supplementary Figure S1).
We also evaluated transcript levels of four 
SMYD3putative targets: AR, c-Met, MMP-9 and Nkx2.8 
[7, 15, 18, 22]. Although no significant alterations in 
AR transcript expression levels were found, in both cell 
lines, mRNA levels of c-Met, MMP-9 and Nkx2.8 were 
significantly increased in silenced LNCaP cells but not 
in SMYD3-silenced PC3 cells, in which a decrease was 
observed (Supplementary Figure S2).
DISCUSSION
PCa is one of the most prevalent cancers and 
a leading cause of mortality and morbidity [23]. The 
growing concern about overdiagnosis and consequent 
overtreatment of PCa patients due to PSA screening should 
be addressed through the identification of those cancers 
Figure 3: In vivo effect of SMYD3 silencing in tumor formation and angiogenesis in PCa cell lines. A. Graphic depiction 
of tumor areas measured in histological sections. B–C. Representative images of CAM assay 6 days after injection of LNCaP (B) or PC3 
(C) sh-scramble or sh-SMYD3 cells (n = 10 for each experimental condition). Images were taken in ovo and ex ovo (original magnification: 
x 10), as well as from histological sections (original magnification: x 40). *p < 0.05 (Mann-Whitney U-test).
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Figure 4: Effects of SMYD3 on global histone patterns. Protein expression levels of H3K4me1, H3K4me2, H3K4me3, H3K27me3 
and H4K20me3 marks in LNCaP A. and PC3 B. sh-scramble and sh-SMYD3 cells. Optical densities were normalized to histone-H3 or 
histone-H4 (mean ± SD, n = 3).
Figure 5: Impact of normal or mutant SMYD3 in the malignant phenotype of PC3 cells. Cell viability, apoptosis levels and 
invasion capability were assessed in sh-SMYD3 PC3 cells and in sh-SMYD3 cells with forced expression of SMYD3 (fSMYD3) and with 
expression of a mutant protein with deletion of EEL (∆EEL) or NHSC (∆NHSC) region of SMYD3 SET domain. A. The efficiency of transfection 
in sh-SMYD3 was confirmed at mRNA level, using real-time RT-PCR. No significant differences in efficiency of transfection were apparent. B. 
Quantification of cell viability was performed by MTT assay after 72 h of culture. C. Quantification of apoptosis levels by APOPercentage kit 
was assessed after 72 h in culture. D. Invasive ability was evaluated by a Matrigel Invasion assay after 24 h of culture. Results were normalized 
to the data obtained with the SMYD3 normal protein (mean ± SD, n = 3). *p < 0.05, **p < 0.01 (Mann-Whitney U-test).
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Figure 6: Identification of putative SMYD3 target genes and its regulation by SMYD3 histone marks. A. Quantification 
of expression by custom made expression arrays of genes involved in cell cycle, apoptosis, DNA repair, mTOR or MAPK/ERK pathways 
normalized to sh-scramble in LNCaP or PC3 cells. B. Expression levels of CCND2 using real-time RT-PCR and Western blot in both sh-
scramble and sh-SMYD3 LNCaP and PC3 cell lines. C. Schematic representation of SMYD3 recognition sequences in Cyclin D2 promoter, 
used for ChIP assay. D. Chromatin immunoprecipitation assay for H3K4me3, H3K27me3, and H4K20me3 marks in CCND2 promoter; 
primers A were located more distant upstream of Transcriptional Start-Site (-1734 bp), B (-1130 bp) and C (-840 bp) were the closest.
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that are most likely to cause clinically aggressive disease. 
Since current clinical and pathological parameters have a 
limited ability to discriminate between clinically significant 
and insignificant PCa, emphasis should be placed on a 
deeper understanding of the biology of this neoplasm, 
which might ultimately result in the development of 
more efficient biomarkers. These are mandatory to 
improve disease management and therapeutic decision. 
Because histone methylation seems to play a major role in 
gene expression regulation, epigenetic modifying enzymes 
or histone modification patterns may serve as biomarkers, 
suitable for diagnostic, prognostic or predictive purposes 
in PCa patients. We have previously reported that higher 
expression levels of histone methyltransferase SMYD3 
associate with more advanced stage PCa and these may 
predict unfavorable prognosis independently of Gleason 
score or pathological stage. Thus, in the present study, we 
sought to investigate the biological role of SMYD3 and the 
corresponding post-transduction modifications of histones, 
to determine how these might impact on the malignant 
phenotype of PCa cells.
Because higher expression levels of SMYD3 were 
found in more aggressive PCa, our strategy was based on 
the knockdown of this enzyme to determine its phenotypic 
impact in PCa cells. After achieving a stable decrease in 
SMYD3 expression, cell viability, proliferation, apoptosis, 
migration and invasion ability assays were carried out in 
two PCa cell lines that are thought to largely represent in 
vivo heterogeneity of this neoplasm. Decreased expression 
of SMYD3 attenuated the highly malignant phenotype of 
the androgen-insensitive PC3 cells, whereas, surprisingly, 
cell viability of the androgen-sensitive LNCaP cell line 
was not apparently compromised. Furthermore, SMYD3 
silencing was associated with increased cell death by 
apoptosis, although the underlying mechanism was 
not elucidated. Concerning LNCaP cells, results of cell 
viability and invasive capability assays contrast with 
those recently reported by Liu et al., but parallel their 
results for cell migration and apoptosis levels [18]. The 
discrepancies might be due to differences in methodology 
because the effectiveness of SMYD3 silencing following 
transfection was confirmed both in our study and in that 
of Liu and co-workers [18]. Interestingly, the effect of 
SMYD3 knockdown in LNCaP cells reported by Liu et 
al. mirror those we observed in PC3 cells, which are 
acknowledged as representing a more aggressive phenotype 
of PCa cells. This observation is further supported by the 
downregulation of c-Met, MMP-9 and Nkx2.8 genes, 
which are implicated in cell proliferation, invasion and 
migration, in SMYD3-depleted PC3. It is noteworthy that 
LNCaP cells display low invasion potential, a feature that 
may explain the opposite effect of SMYD3 knockdown 
in the invasion assay of this cell line and the upregulated 
expression of the above mentioned genes. Both LNCaP 
and PC3 cells derive from PCa metastases, although in 
different settings: the former from a lymph node and the 
latter from bone. Systemic metastatic spread requires a 
wider spectrum of biological aggressiveness owing to the 
more adverse environment that cancer cells have to endure 
during dissemination through the bloodstream. Thus, PC3 
cells display a more aggressive phenotype compared to 
LNCaP, implying that the baseline for each functional assay 
is different for each cell line. Globally, however, the results 
reported for SMYD3 silencing in PCa cells are in line with 
those reported for hepatocellular, colorectal, cervical and 
breast cancers, which further supports an oncogenic role 
Figure 7: Immunoexpression of SMYD3 and Cyclin D2 in prostate cancer tissues. A. Distribution of SMYD3 and Cyclin 
D2 immunoexpression in 150 primary prostate cancer tissues according to immunoscore [1+ (expression lower than in normal prostate 
tissue), 2+ (expression similar to normal prostate tissue), and 3+ (expression higher than in normal prostate tissue)], B. Illustrative images 
of SMYD3 and CCND2 immunoexpression in primary prostate cancer tissues.
Oncotarget9www.impactjournals.com/oncotarget
for SMYD3. In fact, functional in vitro studies showed that 
SMYD3 knockdown was associated with growth inhibition, 
apoptosis and reduced migration/invasion potential in 
cancer cell lines of those tumors [7, 11–14].
To further characterize the effect of SMYD3 
silencing in PCa cells, an in vivo model (the CAM assay) 
was conducted. A significant decrease in tumor formation 
was depicted in sh-SMYD3 PC3 cells, although not 
in LNCaP cells. The higher biological aggressiveness 
of PC3 cells might explain the results observed for 
tumor formation. However, in a mouse model, SMYD3 
knockdown was able to reduce tumor formation by LNCaP 
cells [18], but PC3 cells were not tested. Moreover, it 
has previously demonstrated that SMYD3 methylates 
VEGFR1 protein, increasing its kinase activity [10], 
and, thus, we hypothesized that SMYD3 overexpression 
might have an impact in new vessel formation in the 
in vivo model. However, no significant differences in linear 
microvessel density were apparent in both cell lines tested. 
Although mammalian mice models are more close to the 
biological conditions found in humans, the CAM assay 
has been used as an alternative, owing to its lower cost and 
less strict regulations [24, 25]. As previously mentioned 
by others and taking in consideration our results, CAM 
assay has been shown to a reliable approach compared 
to standard mice models for detection of alterations in 
tumor formation [26, 27]. Indeed, we showed different 
results in cell lines with distinctive aggressiveness, further 
supporting the results observed in the in vitro phenotypic 
assays.
Since SMYD3 establishes H4K20 di- and 
trimethylation and H3K4 trimethylation, the global 
levels of the three states of methylation of H3K4 and 
also H4K20me3 mark were assessed for LNCaP and 
PC3 cells. Furthermore, H3K27me3 levels were also 
assessed because it was previously hypothesized that 
SMYD3 could inappropriately bind to its target genes 
and competing with the silencing activity of repressive 
complexes [28]. No significant differences were apparent 
for any posttranslational marks in both cell lines. 
Interestingly, a similar global trend was observed both in 
SMYD3-silenced LNCaP and PC3. Indeed, slightly higher 
H3K27me3 and decreased H3K4me and H4K20me3 
levels were found in both cell lines after SMYD3 
silencing. On one hand, our findings are in line with the 
aforementioned hypothesis [28], although, on the other, 
no direct effect on the global levels of the marks directly 
catalyzed by SMYD3 was apparent, most probably due 
to the fact that there are several enzymes responsible for 
catalyzing the same marks. Because phenotypic effects 
were apparent in both tested cell lines, it is plausible that 
altered SMYD3 expression could only specifically affect 
the H3K4me status of its target genes, which might not 
be of sufficient magnitude to significantly alter the global 
H3K4 methylation levels.
In accordance with previous findings in other tumor 
models [7, 29], we hypothesized that the oncogenic 
properties of SMYD3 could depend on its histone 
methyltransferase activity. We tested this hypothesis by 
means of transfecting sh-SMYD3 cancer cells with a 
SMYD3 gene mutated at the either the EEL or the NHSC 
amino acid sequences of the SET domain. Phenotypic 
assays demonstrated that the effects of a mutated SET 
domain largely overlap those of SMYD3 silencing, 
meaning that a functional SET domain is necessary for 
PCa cell lines malignant phenotype. Indeed, mutant forms 
behave similarly to sh-SMYD3 suggesting that mutated 
SMYD3 without a functional SET domain was not able 
to increase cell viability or rescue cells from apoptosis, 
for both mutations (∆EEL and ∆NHSC). Although it has 
been reported that the two regions of the SET domain 
have similar roles [29], we found that the EEL domain 
was more closely associated with SMYD3 tumorigenic 
properties in PCa cells. It should be recalled, however, 
that previous observations were made in breast cancer cell 
lines and we are the first to report this effect in PCa cells. 
Thus, different gene sets might be affected in different 
tumor models and the two regions of the SET domain 
might have different affinity for specific gene sequences. 
Although this experiment strongly suggests that SMYD3 
histone methyltransferase activity might be the most 
important for oncogenesis, the possible contribution of 
its enzymatic activity on cytoplasmic proteins can not be 
excluded.
Owing to the phenotypic effects observed due 
to SMYD3 silencing, we then searched for possible 
target genes, focusing on some critical genes from 
relevant cellular pathways frequently deregulated in 
tumorigenesis. Surprisingly, distinct trends in gene 
expression were observed in LNCaP and PC3 cells, 
probably reflecting the different biology and malignant 
phenotype of these two PCa cell lines, which may 
explain, at the least partially, the dissimilar results of 
SMYD3 silencing on the phenotype of LNCaP and PC3 
cells. As stressed above, the different origins of LNCaP 
and PC3, which seem to determine their phenotype, are 
likely to be reflected at genomic and transcript levels 
through different patterns of activity of genes involved in 
critical cellular pathways.
Interestingly, one gene involved in cell cycle 
regulation – CCND2 – showed a similar expression pattern 
in both cell lines, i.e., its expression was restored following 
SMYD3 knockdown. These results strongly suggested that 
CCND2 was a putative target gene of SMYD3. Although 
at protein level, assessed by immunohistochemistry, no 
significant inverse correlation was depicted, both frequent 
SMYD3 overexpression and Cyclin D2 underexpression 
were observed in primary PCa. Interestingly, higher 
SMYD3 protein levels were associated with higher 
Gleason score suggesting that this alteration might be 
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associated with increased tumor aggressiveness, in line 
with previous observations [21] and providing further 
support for an oncogenic role in PCa.
Both aberrant promoter methylation and histone 
acetylation have been implicated in the frequent CCND2 
downregulation observed in PCa [30–32]. Furthermore, 
the CCND2 promoter contains DNA sequences 
5′-CCCTCC-3′ or 5′-GGAGGG-3′, which are specifically 
recognized by SMYD3 for its transcriptional regulatory 
functions [7]. Thus, we interrogated the histone marks in 
the promoter region of CCND2 containing those motifs, 
using the ChIP assay. Although no significant differences 
were found for H3K4 or H3K27 methylation levels, a 
significant decrease in the H4K20me3 mark was apparent 
in sh-SMYD3 PCa cells.
Because the H4K20me3 repressive mark is also 
catalyzed by SMYD3 [8], our results indicate that 
SMYD3 overexpression might be also involved in 
CCND2 silencing in PCa. These findings are in line 
with those of cell cycle analysis, in which an S phase 
arrest was depicted for PC3 SMYD3-depleted cells. 
The fact that methylation levels of CCND2 promoter 
remained unaltered upon SMYD3 silencing, indicates 
that SMYD3′s action at CCND2 promoter is only by is 
histone methyltransferse activity SMYD3. Interestingly, 
epigenetic deregulation of androgen receptor expression 
due to SMYD3 overexpression has been reported in 
LNCaP cells [18] and SMYD3 may also directly interact 
with other nuclear receptors, such as estrogen receptor 
[29], further reinforcing its oncogenic role. However, in 
our study we were not able to confirm AR as a SMYD3 
target, as previously reported.
CONCLUSIONS
In conclusion, our data provide further evidence 
to sustain an oncogenic role for SMYD3 in prostate 
carcinogenesis. In addition to its usefulness as a biomarker 
for clinically aggressive disease, SMYD3 overexpression 
might also constitute an attractive therapeutic target in 
PCa because its tumor-promoting properties are mostly 
due to its histone methyltransferase activity. Indeed, 
SMYD3 silencing might be able not only to restrain the 
expression of proto-oncogenes but also to restore the 
expression of genes inadequately silenced in PCa. A more 
comprehensive and detailed characterization of SMYD3 
target genes is, however, mandatory to fully elucidate its 
role in prostate tumorigenesis.
METHODS
Cell lines and culture conditions
Human PCa cell lines LNCaP, PC3 and VCaP 
were kindly provided by Prof. Ragnhild A. Lothe from 
the Department of Cancer Prevention at the Institute for 
Cancer Research, Oslo, Norway, and DU145 was offered 
by Prof. Fátima Baltazar from the Life and Health Sciences 
Research Institute at the University of Minho, Braga, 
Portugal. All cell lines were maintained in recommended 
medium, supplemented with 10% Fetal Bovine Serum 
(FBS; GIBCO, Invitrogen, Carlsbad, CA, USA) and 1% 
penicillin/streptomycin solution (GIBCO, Invitrogen), at 
37ºC;C and 5% CO2. PCa cell lines were karyotyped by 
G-banding (for validation purposes) and routinely tested 
for Mycoplasma spp. contamination (PCR Mycoplasma 
Detection Set, Clontech Laboratories Inc., Mountain View, 
CA, USA).
Generation of sh-SMYD3 silenced cell lines
SMYD3 knockdown was performed through 
viral transduction in LNCaP and PC3 cell lines using 
shRNA Lentiviral Particles (sc-61576-V; Santa Cruz 
Biotechnology Inc., Santa Cruz, CA) in the presence of 
polybrene (Santa Cruz Biotechnology Inc.) as described 
by the manufacturer. Additionally, control LNCaP and 
PC3 cells were generated using a non-target scramble 
shRNA (sc-108080; Santa Cruz Biotechnology Inc.). After 
transduction, stable clones with shRNA were selected 
with Puromycin dihydrochloride (cat. 631306, Clontech 
Laboratories Inc.) at a final concentration of 2 μg/ml or 4 
μg/ml in LNCaP or PC3 cells, respectively.
Protein extraction and western blot analysis
Cells were collected with a gum rubber-scraping 
device, lysed with RIPA buffer (sc-24948, Santa Cruz 
Biotechnology Inc.) and protein concentration was 
determined using BCA assay (Thermo Scientific, Waltham, 
MA, USA) according to manufacturer’s information. 
Subsequently, 30 μg of total protein were separated by 
SDS-PAGE, transferred to nitrocellulose membranes and 
incubated with antibodies against anti-SMYD3 (dilution: 
1:500, Abcam, Cambridge, UK), against anti-CCND2 
(dilution: 1:500, Cell Signaling, Danvers, MA, USA), 
anti-H3K4me1 (dilution: 1:1000, Abcam), anti-H3K4me2 
(dilution: 1:1000, Abcam), anti-H3K4me3 (dilution: 1:400 
Abcam), anti-H3K27me3 (dilution: 1:500 Millipore, 
Billerica, MA, USA), anti-H4K20me3 (dilution: 1:500 
Active Motif, Carlsbad, CA, USA) and as input control 
anti-histone H3 rabbit antibody (dilution: 1:500, Abcam), 
anti-histone H4 rabbit antibody (dilution: 1:500, Abcam) 
and β-actin (dilution: 1:8000, Sigma-Aldrich, Schnelldorf, 
Germany), when appropriate. The blots were developed 
using Immun-Star™ WesternC™ Kit according to 
manufacturer’s indications (BioRad, Hercules, CA, 
USA). All the experiments were performed in triplicate. 
Relative optical density determination was performed 
using QuantityOne® Software version 4.6.6. (Biorad) and 
proteins levels were normalized using β-actin levels as 
reference.
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Cell viability assay
The effect of SMYD3 on cell viability was 
assessed in triplicates by 3-(4, 5-dimethylthiazol-2-yl)-2, 
5-diphenyltetrazolium (MTT; Sigma-Aldrich) assay. 
The cells were seeded in 96-well plates at a density of 
1 × 104 cells/well and after 24, 48 and 72 h, cells were 
incubated with MTT at 37ºC; C for 2 h and the reaction 
was stopped by the addition of 100 μl/well of Dimethyl 
sulfoxide (DMSO) (Sigma-Aldrich) lysing for 10min. An 
automated plate reader (FLUOstar Omega, BMG Labtech, 
Offenburg, Germany) at 540 nm with a reference filter 
of 630nm allowed for colorimetric quantification. The 
absorbance value was directly proportional to the number 
of viable cells.
Cell cycle analysis
Cell cycle distribution of SMYD3 knockdown and 
scramble PCa cells was determined by flow cytometry. 
Briefly, 5 × 105 harvested cells were fixed overnight at 
4ºC;C with 70% cold ethanol. After washing with cold 
PBS, cells were ressuspended in staining Propidium 
Iodide Solution (Cytognos S.L, Salamanca, Spain) and 
incubated for 30 minutes at room temperature. All cells 
were then measured on a Cytomics FC500 flow cytometer 
(Beckman Coulter, Fullerton, CA, USA) and analyzed 
using Modfit LT (Verity Software House, Inc, Topshan, 
Maine, USA). Three biological replicates were performed 
for sh-scramble and sh-SMYD3.
Cell proliferation analysis
Cell proliferation was evaluated using a colorimetric 
immunoassy (Cell Proliferation ELISA BrdU, Roche, 
Mannheim, Germany) at 72 hours in scramble and 
SMYD3-depleted PC-3 cells. Briefly, PCa cells were 
exposed to the pyridine analogue bromodeoxyuridine 
(BrdU) during 24 hours. After incorporation into DNA, 
BrdU was detected by immunoassay, according to 
manufacturer’s instructions. Absorbance was measured 
at 370 nm in a microplate reader (FLUOstar Omega, 
BMG Labtech, Offenburg, Germany), subtracting the 
background, at 492 nm. Absorbance values directly 
correlate with the amount of DNA synthesis and with 
the number of proliferating cells. Three replicates 
were performed for each condition, and at least three 
independent experiments were carried out.
Apoptosis assay
Apoptosis was assessed using the APOPercentage™ 
kit (Biocolor Ltd., Newtownabbey, Northern Ireland, UK). 
LNCaP and PC3 cells were seeded in the same conditions 
as described for MTT assay. Following an incubation 
period of 72 h, the APOPercentage assay was performed 
according to manufacturer’s instructions. Quantification of 
apoptosis was achieved by measuring the optical density 
of the released dye at 550nm with a reference filter of 
620nm using a FLUOstar Omega microplate reader. To 
normalize the OD measured in the apoptosis test to the 
cell number, the OD of apoptosis assay was divided by 
the OD of the viability assay, also performed in 96-well 
plates. The results of the apoptosis assay on the silenced 
cells were expressed as the ratio of the values obtained for 
scramble cells.
Migration assay
The ability of cells of each genotype to migrate into 
a defect in a monolayer culture was determined using the 
wound healing assay. Cells were grown to full confluence in 
24-well plates and scratches were performed using a 100μL 
tip. The medium was removed, and cells were washed with 
PBS and medium replaced. Scratch closure was analyzed 
under the microscope and images were captured at different 
time points. The calculations were made according to the 
formula [(S Time zero-S Time point/ S Time zero) x 100, 
where S = Distance)].
Invasion assay
Invasion capacity was analyzed through Biocoat 
Matrigel Invasion Chambers (BD Biosciences, Franklin 
Lakes, NJ, USA) according to manufacturer’s protocol. 
Briefly, cells were placed in Matrigel inserts and allowed 
to migrate for 24 or 48 h at 37ºC;C. Non-migrating cells 
were removed from the top of the filter and cells that 
migrated were fixed in methanol and stained with DAPI. 
Migrated cells were manually counted and results were 
displayed as percentages of invasion relative to scramble.
Chick chorioallantoic membrane (CAM) assay
To assess in vivo tumor formation and angiogenesis, 
the CAM assay was used, as previously described [33], 
with some modifications. Briefly, fertilized chicken eggs 
(Pinto Bar, n = 5 for each experiment) were incubated at 
37ºC;C and 70% humidity. On day 3 of development, after 
puncturing the air chamber, a hole in a specific region of 
the eggshell was performed and eggs were sealed with 
tape and returned to the incubator. On day 10, a small 
plastic ring was placed on the CAM and 5 × 106 PCa cells 
(PC3 or LNCaP, control and sh-SMYD3), ressuspended 
in 20 μL of RPMI or RPMI/F12 medium, were injected 
in the ring over the CAM. On day 14, the tumor formed 
was photographed in ovo using a stereomicroscope 
(Olympus S2x16, Olympus, Tokyo, Japan) and, on day 
16, chicks were sacrificed at –80ºC; C for 10 minutes. The 
CAM and tumors were fixed with 4% paraformaldehyde 
and photographed ex ovo. Samples (n = 10 for each 
experimental condition) were paraffin-embedded, 
sectioned, and stained with hematoxylin and eosin (HE) 
for histological analysis. The total area occupied by tumors 
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was measured using the Cell B software (Olympus) and 
linear vessel density was assessed by calculating the ratio 
between the number of vessels and the total length of the 
membranes.
Mutagenesis and Transient transfection assays
For bacterial expression, SMYD3 cDNA (Origene 
Technologies Rockville, MD, USA) was firstly 
deleted at NHSC or EEL motifs using specific primers 
(Supplementary Table S2) of the QuikChange II Site-
Directed Mutagenesis Kit (Agilent Technologies, Santa 
Clara, CA, USA). After bacterial transformation, 
colonies were picked and the plasmids were purified 
using the Qiagen Plasmid Miniprep Kit (Qiagen, Hilden, 
Germany). Subsequently, deletions were confirmed 
by direct sequencing in an ABI PRISM 310 automatic 
sequencer using Big Dye Terminator Chemistry (Applied 
Biosystems, Foster City, CA, USA), according to the 
manufacturer’s recommendations. Expression plasmids 
encoding the mutant SMYD3 (∆NHSC or ∆EEL) or the 
wild type SMYD3 cDNA were transiently transfected into 
sh-SMYD3 PC3 using LipofectAMINE2000 (Invitrogen), 
following manufacturer’s instructions. Phenotypic assays 
for cell viability, apoptosis and invasion were performed 
as described above.
Identification of putative target genes
To assess whether SMYD3 was implicated in 
the regulation of selected genes involved in cell cycle, 
apoptosis, DNA repair, mTOR or MAPK/ERK pathways, 
a custom array panel (Roche Applied Science, Manheim, 
Germany) was designed for quantification of expression of 
those genes. Total RNA was extracted from all cell lines 
using TRIzol® (Invitrogen) according to manufacturer’s 
instructions and cDNA synthesis was performed using 
Transcriptor High Fidelity cDNA Synthesis Kit (Roche) 
according to manufacturer’s instructions. Expression 
levels were determined by real-time PCR in a LightCycler 
480 (Roche Diagnostics) and the amounts of mRNA were 
normalized using GUSB, TFRC and 18S as endogenous 
controls. The comparative Ct method [34] was used to 
calculate fold-difference in gene expression among groups 
and only genes with a logarithmized fold change above 
1.25 or below -1.25 were further considered.
Validation of target genes by quantitative RT-
PCR (qRT-PCR)
After gene selection, mRNA levels were confirmed 
in the LNCaP and PC3, both scramble and sh-SMYD3. A 
total of 1000ng was reverse transcribed using HighCapacity 
cDNA reverse transcription kit (Applied Biosystems) 
according to manufacturer’s instructions. Expression levels 
were evaluated using TaqMan® Gene Expression Assays 
for AR, CCND2, C-Met, MMP9 and Nkx2.8 (Applied 
Biosystems) and GUSB was used as a reference gene. 
Each plate included multiple non-template controls and 
all experiments were run in biological and methodological 
triplicates. Results were always normalized for the result of 
scramble cell lines established as 1.
Methylation analysis
DNA extraction from cell lines was performed 
using a standard technique comprising digestion with 
proteinase K (20mg/mL) in the presence of 10% SDS 
at 55°C, followed by phenol-chloroform extraction and 
precipitation with 100% ethanol. One microgram of DNA 
was submitted to bisulfite modification using the EZ 
DNA MethylationGold™ Kit (Zymo Research, Orange, 
CA) according to manufacturer instructions. Specific 
CCND2 primers and TaqMan probe were designed using 
the Methyl Primer Express Software v1.0 (Applied 
Biosystems). β-actin (ACTB) was used as an internal 
reference gene to normalize for DNA input. CCND2 
methylation levels were calculated after normalization 
for ACTB and PC-3 and LNCaP scramble samples served 
as controls to ascertain differential methylation upon 
SMYD3 silencing.
Chromatin immunoprecipitation (ChIP) Assay
ChIP assay was performed using EZ-Magna ChIP 
G-Chromatin Immunoprecipitation Kit and the Magna 
Grip Rack (Millipore), according to the manufacturer’s 
instructions. For each assay, anti-H3K4me3, anti-
H3K27me3, anti-H4K20me3, anti-H3, anti-H4 (all from 
Abcam) and the negative control provided with the kit 
(normal mouse IgG), were used. DNA quantification 
was performed in a 7500 Real- Time PCR System 
(Applied Biosystems), using Power SYBR Green PCR 
Master Mix (Applied Biosystems). Three gene-specific 
pairs of primers for each gene promoter were used, in 
which primers A were located more distant upstream of 
Transcriptional Start-Site (TSS) and C those that were 
closer to TSS (Figure 6C and Supplementary Table S2). 
The relative amount of promoter DNA was calculated 
for each histone mark over the core histone (H3 or H4) 
and normalized using Input Percent Method as previously 
described by our group [35].
Immunohistochemistry
Immunohistochemistry was performed using the 
Novolink™ Max Polymer Detection System (Leica 
Biosystems, Germany]. Sections (3 μm thick) from 
formalin-fixed and paraffin-embedded tissues of a cohort 
of 150 primary PCa were used (Supplementary Table S3). 
Antigen retrieval was accomplished by microwaving the 
specimens at 800W for 20–30 minutes in EDTA buffer. 
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After cooling the slides, endogenous peroxidase activity 
was blocked by incubating the sections in hydrogen 
peroxide in 3% methanol for 30 minutes. Primary 
monoclonal antibodies for SMYD3 (#61407, Active 
Motif, Carlsbad, CA, USA) and Cyclin D2 (clone D52F9, 
Cell Signaling, Danvers, MA , USA) were used in 1:300 
and 1:200 dilution, respectively, with 1% PBS-BSA and 
incubated at 4ºC;C overnight. Then, 3, 3′-diaminobenzidine 
(Sigma-Aldrich™, Germany) was used for visualization 
and hematoxilin for nuclear counterstaining. Finally, after 
dehydration and diaphanization, slides were mounted 
with Entellan® (Merck-Millipore, Germany). Seminal 
vesicle and colon tissue sections showing intense 
immunoreactivity for SMYD3 and Cyclin D2 were used 
as positive controls, respectively. The negative control 
consisted on the omission of the primary antibodies. 
Slides were observed at the optical microscope and 
evaluated for SMYD3 and CCND2 immunoexpression 
by an experienced Uropathologist. Scoring criteria were: 
0 – no immunoexpression; +1 – immunoexpression 
lower than in normal prostate epithelial cells; +2 – 
immunoexpression similar to normal prostate epithelial 
cells; +3 – immunoexpression higher than in normal 
prostate epithelial cells.
Statistical analysis
The Shapiro-Wilk’s W test allowed for the 
examination of the appropriateness of a normal distribution 
assumption for each of the parameters (data not shown). 
For in vitro and in vivo assays, comparison between two 
groups was performed using the Mann–Whitney U­test. 
Differences in immunoexpression frequencies, as well as 
associations with clinicopathological parameters, were 
assessed using the Chi-square test. All statistical tests 
were 2-sided. Statistical analysis was carried out using 
Graph Pad Prism version 5. Significance level was set at 
p < 0.05.
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